The Journal of Immunology, Vol 148, Issue 2 498-502, Copyright © 1992 by American Association of Immunologists

ARTICLES

Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor

MH Holguin, CB Martin, NJ Bernshaw and CJ Parker
Department of Medicine, University of Utah School of Medicine, Salt Lake City.

E from individuals with the Inab blood group phenotype have an isolated deficiency of decay accelerating factor (DAF, CD55). DAF is a glycosyl phosphatidylinositol anchored membrane protein that inhibits activation of both the classical and alternative pathways of complement. Deficiency of DAF from the E of paroxysmal nocturnal hemoglobinuria (PNH) is thought to contribute to their greater sensitivity to complement-mediated lysis. Unlike PNH E, however, Inab cells are not susceptible to acidified serum lysis, a process that is mediated through activation of the alternative pathway. This observation led us to hypothesize that membrane constituents other than DAF control susceptibility to acidified serum lysis. To investigate this hypothesis, Inab E were incubated in acidified serum, and hemolysis and C3 deposition (as a measure of alternative pathway activation) were quantitated. C3 deposition of Inab cells was approximately 20 times greater than normal, however, hemolysis was not observed. Inab E expressed a normal amount of membrane inhibitor of reactive lysis (MIRL, CD59), a glycosyl phosphatidylinositol anchored protein that is also deficient in PNH. When MIRL function was blocked with antibody, C3 deposition markedly increased, and 100% of the Inab cells hemolyzed in acidified serum. These studies demonstrate that susceptibility to acidified serum lysis is controlled primarily by MIRL, and that in addition to its regulatory affect on the membrane attack complex, MIRL also modulates the activity of the C3 convertase of the alternative pathway by a mechanism that remains to be determined.

This article has been cited by other articles:

				E. K. MIBEI, A. S. S. ORAGO, and J. A. STOUTE IMMUNE COMPLEX LEVELS IN CHILDREN WITH SEVERE PLASMODIUM FALCIPARUM MALARIA Am J Trop Med Hyg, May 1, 2005; 72(5): 593 - 599. [Abstract] [Full Text] [PDF]

				M. Jasinski, P. Pantazopoulos, R. P. Rother, N. van Rooijen, W.-C. Song, H. Molina, and M. Bessler A novel mechanism of complement-independent clearance of red cells deficient in glycosyl phosphatidylinositol-linked proteins Blood, April 1, 2004; 103(7): 2827 - 2834. [Abstract] [Full Text] [PDF]

				P. Hillmen, C. Hall, J. C.W. Marsh, M. Elebute, M. P. Bombara, B. E. Petro, M. J. Cullen, S. J. Richards, S. A. Rollins, C. F. Mojcik, et al. Effect of Eculizumab on Hemolysis and Transfusion Requirements in Patients with Paroxysmal Nocturnal Hemoglobinuria N. Engl. J. Med., February 5, 2004; 350(6): 552 - 559. [Abstract] [Full Text] [PDF]

				X. Sun, C. D. Funk, C. Deng, A. Sahu, J. D. Lambris, and W.-C. Song Role of decay-accelerating factor in regulating complement activation on the erythrocyte surface as revealed by gene targeting PNAS, January 19, 1999; 96(2): 628 - 633. [Abstract] [Full Text] [PDF]